Selective removal efficacy and safety of centrifugal filtration plasmapheresis in the treatment of neuroimmunological diseases
10.13303/j.cjbt.issn.1004-549x.2026.10.006
- VernacularTitle:离心式膜滤过血浆置换治疗神经免疫性疾病的选择性清除效应及安全性研究
- Author:
Xinfang ZHU
1
;
Yuzong ZHOU
1
;
Yao ZHONG
1
;
Fei SUN
1
;
Qingmei GAO
1
;
Wangsheng CHEN
1
;
Rong XIA
1
Author Information
1. Department of Blood Transfusion, Huashan Hospital, Fudan University, Shanghai 200040, China
- Publication Type:Journal Article
- Keywords:
plasma exchange;
centrifugal filtration plasmapheresis;
neuroimmunolo- gical diseases;
plasma sparing;
fibrinogen;
cryoprecipitate
- From:
Chinese Journal of Blood Transfusion
2026;39(10):1355-1363
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To compare the effects of centrifugal filtration plasmapheresis (CFPP) and centrifugal plasma exchange (PE) on globulin, albumin, coagulation function and blood cells in patients with neuroimmunological diseases, so as to provide evidence for the formulation of treatment protocols and the selection of parameters during clinical practice. Methods: A total of 74 patients (88 treatment courses) with neuroimmunological diseases who underwent therapeutic plasma exchange in our hospital were retrospectively enrolled, including 45 patients (57 courses) in the CFPP group and 29 patients (31 courses) in the PE group; 53 treatment sessions from 13 of these patients constituted the single-session analysis set. The CFPP group was further divided into regimen A (Cascadeflo EC-20W with a plasma-discard fraction of 15%) and regimen B (Cascadeflo EC-30W with a plasma-discard fraction of 10%). The percentage changes and absolute changes of 14 laboratory parameters before and after treatment were compared between groups. The influence of cryoprecipitate supplementation on the change in Fibrinogen (ΔFib) was further compared, and the determinants of ΔFib were identified by univariable and multivariable analyses, using multiple linear regression at the cohort level and a linear mixed-effects model with patient as a random intercept at the single-session level. Results: The removal effect of CFPP was highly selective: Fib, globulin, D-dimer and FDP decreased by 20%–50%, whereas the changes in INR, PT, APTT, TT and AT-Ⅲ ranged only from-5.2% to +1.4%, none of which was statistically significant. The removal intensity of regimen A was greater than that of regimen B, which in turn was greater than that of PE (Fib -46.5%, -38.6% and -20.0%; globulin -43.3%, -33.4% and -17.9%; both between-group P<0.001). Albumin was also removed to varying degrees, but the between-group difference was not significant (P=0.077). The decreases in globulin and Fib were significantly greater in the CFPP group than in the PE group (-10.0 vs -5.0 g/L, P=0.002; -1.1 vs -0.8 g/L, P=0.012), whereas the between-group differences in the losses of albumin, Hct and PLT did not reach statistical significance (albumin: median difference-2.0 g/L, 95%CI -4.0 to 0.0, P=0.134). In a single session, Fib decreased from 2.00 to 1.60 g/L in the CFPP group (P=0.003), with no significant change in the PE group (P=0.444); after adjustment for the volume of cryoprecipitate transfused, post-treatment Fib was 71.4% higher in the PE group than in the CFPP group (P<0.001); cryoprecipitate was used in 84.2% (48/57) of CFPP courses and 22.6% (7/31) of PE courses. In the multivariable analysis, only pretreatment Fib was independently associated with ΔFib (β=0.726 g/L, 95%CI 0.316-1.135, P<0.001). The volume of replacement fluid per session was (467±153) mL for CFPP versus (2 132±395) mL for PE, a reduction of approximately 78%. The incidence of adverse reactions was 8.0% (7/88 courses), all of which were mild to moderate. Conclusion: In patients with neuroimmunological diseases, CFPP achieves stronger and more selective removal of macromolecules than conventional centrifugal PE without significantly increasing the loss of albumin or blood cells, and at the same time substantially saves plasma resources. The decrease in Fib was the most prominent and clinically significant consequence of CFPP in this study, and can be managed by monitoring Fib and supplementing cryoprecipitate or Fibrinogen concentrate to improve coagulation function.